Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.

BACKGROUND AND AIM

The most effective way to control severity and mortality rate of the novel coronavirus disease (COVID-19) is through sensitive diagnostic approaches and an appropriate treatment protocol. We aimed to identify the effect of adding corticosteroid and Tocilizumab to a standard treatment protocol in treating COVID-19 patients with chronic disease through hematological and lab biomarkers.

MATERIALS AND METHODS

This study was performed retrospectively on 68 COVID-19 patients with chronic disease who were treated by different therapeutic protocols. The patients were categorized into four groups: control group represented the patients' lab results at admission before treatment protocols were applied; group 1 included patients treated with anticoagulants, Hydroxychloroquine, and antibiotics; group 2 comprised patients treated with Dexamethasone; and group 3 included patients treated with Dexamethasone and Tocilizumab.

RESULTS

The WBC and neutrophil counts were increased significantly in group 3 upon the treatment when they were compared with patients in group 1 ( = 0.004 and  = 0.001, respectively). The comparison of C-reactive Protein (CRP) level at admission was higher in group 3 than in group 1 with  = 0.030. After 10 days of treatment, CRP level was decreased in all groups, but in group 3 it was statistically significant ( = 0.002).

CONCLUSION

The study paves the way into the effectiveness of combining Dexamethasone with Tocilizumab in treatment COVID-19 patients with chronic diseases.